http://pharmexec.findpharma.com/pharmexec The publisher of Pharmaceutical Executive brings visitors PharmExec.com, which serves up a daily dose of news and features from the world of pharma business and marketing. 2010-03-17T05:59:22Z http://pharmexec.findpharma.com/pharmexec/NCM---Bold-Brands-Drive-Revenue-with-Storytelling/ArticleStandard/Article/detail/661423?ref=25 NCM - Bold Brands Drive Revenue with Storytelling 2010-03-16T04:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/122010/661423null HTML http://pharmexec.findpharma.com/pharmexec/Europe/New-Insights-Into-Open-innovation/ArticleStandard/Article/detail/660965?ref=25 Open innovation is sometimes chaotic and often difficult to measure, but getting it right can give firms a real edge now and in the future. 2010-03-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/112010/660965null HTML http://pharmexec.findpharma.com/pharmexec/2010-prix-galien-brochure-with-jay/ArticleStandard/Article/detail/661046?ref=25 2010 prix galien sponsor brochure with jay 2010-03-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/112010/661046null PDF http://pharmexec.findpharma.com/pharmexec/Europe+Features/Mentoring-the-Mavericks/ArticleStandard/Article/detail/660982?ref=25 Having a 'maverick' in your company can lead to problems as well as breakthroughs and innovations. Judith Germain outlines the value of harnessing a brilliant but wayward talent. 2010-03-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/112010/660982null HTML http://pharmexec.findpharma.com/pharmexec/R%26D/Two-Drugs-Fail-in-Trials/ArticleStandard/Article/detail/660853?ref=25 Monday was a gloomy day for industry as two separate drug trials went belly up. AstraZeca's Recentin proved that it wasn't up-to-snuff compared with Avastin, and the Roche/Biogen Idec arthritis collaboration treatment, ocrelizumab, may have led to fatalities. 2010-03-10T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/112010/660853null HTML http://pharmexec.findpharma.com/pharmexec/2010-prix-galien-sponsorship-guide/ArticleStandard/Article/detail/660633?ref=25 2010 prix galien sponsorship guide 2010-03-09T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/112010/660633null PDF http://pharmexec.findpharma.com/pharmexec/Europe+News/Report-Predicts-Major-Slowdown-for-Big-Pharma/ArticleStandard/Article/detail/659971?ref=25 4 March, 2010 2010-03-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/102010/659971null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/FDA-Gives-Red-Light-to-Ranbaxy-for-Generic-Flomax/ArticleStandard/Article/detail/659857?ref=25 The Indian generic firm Ranbaxy was dealt another blow this week as its version of the enlarged prostate drug Flomax was denied approval in the US just as it was about to go to market. 2010-03-03T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/102010/659857null HTML http://pharmexec.findpharma.com/pharmexec/Deals/Astellas-Hostile-Takeover-Turns-Even-More-Hostile/ArticleStandard/Article/detail/659855?ref=25 The Japan-based company filed a lawsuit against OSI Pharmaceuticals for rejecting its tender offer, but will this strategy work? 2010-03-03T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/102010/659855null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Web-Infinity---And-Beyond/ArticleStandard/Article/detail/659860?ref=25 Three ad agencies came up with two similarly designed ways of keeping track of online healthcare conversation, harnessing the power of social media sites like Twitter and Digg. 2010-03-03T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/102010/659860null HTML http://pharmexec.findpharma.com/pharmexec/Oxford-High-Performance-Leadership-Programme/ArticleStandard/Article/detail/659479?ref=25 Improve your leadership impact 2010-03-02T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/102010/659479null HTML http://pharmexec.findpharma.com/pharmexec/Europe/The-Power-of-Successful-Negotiation/ArticleStandard/Article/detail/659015?ref=25 A corporate focus on negotiation can help organizations reap substantial and measurable benefit, writes Alison Morris. 2010-02-26T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/092010/659015null HTML http://pharmexec.findpharma.com/pharmexec/Europe/Advancing-Drug-Discovery-With-Research-Informatics/ArticleStandard/Article/detail/659059?ref=25 Anirban Ghosh and Siddharth Sawhney explain how research informatics tools can advance the speed and success of drug discovery research. 2010-02-26T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/092010/659059null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/Positive-Outlook-for-UK-Biotech-Jobs/ArticleStandard/Article/detail/659067?ref=25 February 26, 2010. 2010-02-25T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/092010/659067null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Avandia-2-Ethical-Boogaloo/ArticleStandard/Article/detail/658599?ref=25 GSK is coming under serious fire again from the FDA and Senate, who say the company resorted to scientific flimflammery to keep researchers quiet about Avandia's safety risks. 2010-02-24T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/092010/658599null HTML http://pharmexec.findpharma.com/pharmexec/Europe/The-Seven-Deadly-Sins-of-Marketing-Excellence/ArticleStandard/Article/detail/657777?ref=25 Marketing excellence programmes are popular, important and frequently flawed, says Dr Brian D. Smith 2010-02-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/082010/657777null HTML http://pharmexec.findpharma.com/pharmexec/Whitepaper/Gauging-the-Risk-of-Dual-Enrollment/ArticleStandard/Article/detail/657805?ref=25 This Whitepaper explores dual enrollment, or the occurrence of research subjects enrolling in overlapping clinical trials. Its case study formulates a proposed solution in the form of a web-centric registry. 2010-02-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/082010/657805null REMOTE http://pharmexec.findpharma.com/pharmexec/Europe+News/Genzyme-Expands-UK-Site/ArticleStandard/Article/detail/657776?ref=25 February 18, 2010. 2010-02-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/082010/657776null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Merck-Mergers-and-Layoffs-and-Pipelines-Oh-My/ArticleStandard/Article/detail/657590?ref=25 The company released its numbers for 4Q '09, but is still hunting for more annual savings, which could come in the form of up to 15,000 job cuts. 2010-02-17T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/082010/657590null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/Former-Schering-Plough-CEO-Speaks-Out-on-MampAs/ArticleStandard/Article/detail/657354?ref=25 February 16, 2010. 2010-02-16T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/082010/657354null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Study-Links-Paxil-to-Breast-Cancer-Patient-Deaths/ArticleStandard/Article/detail/656474?ref=25 The popular antidepressant is associated with up to 91 percent increase in risk of death in patients undergoing tamoxifen treatment for breast cancer. 2010-02-10T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656474null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/Europe-Reveals-Generic-Dominance/ArticleStandard/Article/detail/656356?ref=25 February 10, 2010. 2010-02-10T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656356null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/No-Real-New-Money-for-Drug-Regulation/ArticleStandard/Article/detail/656473?ref=25 Added funds for FDA to come from new user fees, largely for food and tobacco regulation. 2010-02-10T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656473null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Ernst-amp-Young-Puts-the-Spotlight-on-Pharma-30/ArticleStandard/Article/detail/656475?ref=25 The blockbuster model has been dead for a while, but pharma is just now researching new ways to reach patients. Pharm Exec interviews Carolyn Luce at Ernst & Young to learn more about the new era of pharma outreach and marketing. 2010-02-10T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656475null HTML http://pharmexec.findpharma.com/pharmexec/Independent-Data-Integrator---Clinical-RSVP-Accela/ArticleStandard/Article/detail/656168?ref=25 Independent Data Integrator - Clinical RSVP Accela Form - Gauging the Risk of Dual Enrollment 2010-02-09T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656168null HTML http://pharmexec.findpharma.com/pharmexec/Gauging-the-Risk-of-Dual-Enrollment---Independent-/ArticleStandard/Article/detail/656163?ref=25 Gauging the Risk of Dual Enrollment - Independent Data Integrator - Clinical RSVP Whitepaper 2010-02-09T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656163null PDF http://pharmexec.findpharma.com/pharmexec/Prix-Galien-2010-Sponsorship-Guide/ArticleStandard/Article/detail/655849?ref=25 Prix Galien 2010 Sponsorship Guide 2010-02-08T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/655849null PDF http://pharmexec.findpharma.com/pharmexec/Europe+News/Actavis-Ray-of-Hope-for-Beleaguered-Iceland/ArticleStandard/Article/detail/655842?ref=25 8 February, 2010. 2010-02-08T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/655842null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Proven-Reliability-in-Temperature-Controlled-Shipp/ArticleStandard/Article/detail/655854?ref=25 American Airlines Cargo has implemented a high-visibility, multi-layered system for temperature-controlled shipping that has gained accreditation in 60 cities in 24 countries worldwide. American?s ExpediteTC solution delivers the kind of specialized air cargo expertise demanded by pharmaceutical customers and their freight forwarders. 2010-02-08T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/655854null REMOTE http://pharmexec.findpharma.com/pharmexec/AAC-Accela-Form---Proven-Reliability-in-Temperatur/ArticleStandard/Article/detail/655464?ref=25 AAC Accela Form - Proven Reliability in Temperature Controlled Shipping - PE Whitepaper 2010-02-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062010/655464null PDF http://pharmexec.findpharma.com/pharmexec/AAC-Accela-Form---Proven-Reliability-in-Temperatur/ArticleStandard/Article/detail/655468?ref=25 AAC Accela Form - Proven Reliability in Temperature Controlled Shipping 2010-02-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062010/655468null HTML http://pharmexec.findpharma.com/pharmexec/R%26D/Palpitations-in-the-Heart-of-US-Biotech/ArticleStandard/Article/detail/655245?ref=25 California's biotech industry takes its own pulse in a new survey that tracks how the state is doing in serving as the nation's medicine cabinet and avatar of drug innovation. 2010-02-03T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062010/655245null HTML http://pharmexec.findpharma.com/pharmexec/Sales/Wyeth-Purchase-Boosts-Pfizer-Profits/ArticleStandard/Article/detail/655246?ref=25 Pfizer's strategy to use Wyeth's drug pipeline to increase its sales has paid off as the drug giant announced that its fourth quarter earnings nearly doubled year-to-year. Too bad investors are running in fear of an ugly 2010 forecast. 2010-02-03T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/062010/655246null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/A-Sturdy-Framework/ArticleStandard/Article/detail/656047?ref=25 Improving field force business planning requires managers to run each sales territory as if it is a self-contained business operation. 2010-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656047null XML http://pharmexec.findpharma.com/pharmexec/From+the+Editor/Assets-for-Advantage/ArticleStandard/Article/detail/656048?ref=25 Innovation won't happen until the industry is ready to sit down and make a big change. 2010-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656048null XML http://pharmexec.findpharma.com/pharmexec/Washington+Report/Vaccines-and-Value/ArticleStandard/Article/detail/656049?ref=25 R&D is surging, but new methods and data raise new manufacturing and regulatory challenges. 2010-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656049null XML http://pharmexec.findpharma.com/pharmexec/Sales/Tearing-Up-the-Rule-Book/ArticleStandard/Article/detail/656050?ref=25 Sales compensation practices are due for an overhaul in 2010. 2010-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656050/tearingup_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656050null XML http://pharmexec.findpharma.com/pharmexec/Marketing/Kalido-KONA-Information-Appliance-for-Pharmaceutic/ArticleStandard/Article/detail/654122?ref=25 Today?s rapidly changing commercial and regulatory landscape demands better information faster than ever before. Pharmaceutical companies need to adapt quickly to effectively market and sell products while reducing the cost of sales. The Kalido KONA Information Appliance for Pharmaceutical Sales & Marketing Analytics is a prebuilt, high-performance solution designed to address today?s information needs, with the extensibility and scalability to meet tomorrow?s. 2010-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/654122null REMOTE http://pharmexec.findpharma.com/pharmexec/Strategy/Brand-of-the-Year-Avastin/ArticleStandard/Article/detail/656052?ref=25 As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end. 2010-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656052/Brandoftheyear_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656052null XML http://pharmexec.findpharma.com/pharmexec/Regulatory/Business-Intelligence-Case-study-Abbott-Laboratori/ArticleStandard/Article/detail/654146?ref=25 Abbott Laboratories tapped Kalido?s model-driven data warehousing infrastructure to revamp?and revive?an overworked BI system. Executives can view accurate, timely data in each of several different contexts?historical, current, or future. The new system also gives Abbott?s sales and marketing executives better insight into how efficiently the company is allocating its sales and marketing investments, particularly in emerging markets. 2010-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/654146null REMOTE http://pharmexec.findpharma.com/pharmexec/Europe/EU-Pricing-Dilemmas/ArticleStandard/Article/detail/656074?ref=25 Although representing a huge market, the EU also presents problems that hamper profitability— particularly when it comes to differing price regulations across member states. 2010-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656074null XML http://pharmexec.findpharma.com/pharmexec/Global/New-Challenges-for-NICE/ArticleStandard/Article/detail/656046?ref=25 Last year was a trying one for the UK's National Institute for Health and Clinical Excellence. Will 2010 be any easier 2010-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656046null XML http://pharmexec.findpharma.com/pharmexec/Strategy/Shire-on-the-Wire/ArticleStandard/Article/detail/656051?ref=25 The British specialty shop was once a laughing stock. Now it’s one of pharma’s fastest growing mid-size firms, with a patent cliff bridged and a biotech engine of orphan drugs. So why does CEO Angus Russell fret that success might spoil Shire? 2010-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656051/i2_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656051null XML http://pharmexec.findpharma.com/pharmexec/Technology/Data-Governance-Business-Data-You-Can-Believe-In/ArticleStandard/Article/detail/654143?ref=25 Bad data ? and a lack of good data management practices ? can cost your business millions of dollars every year. You have to treat your data like every other valuable asset in your business: You must protect it, nurture it and ensure that, like any asset, it?s in the best condition possible. 2010-02-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/654143null REMOTE http://pharmexec.findpharma.com/pharmexec/Europe+News/Emergency-Contraception-Drug-Breakthrough/ArticleStandard/Article/detail/653966?ref=25 January 29, 2010. 2010-01-29T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/653966null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/AHF-Puts-Kibosh-on-Merck-Rep-Visits/ArticleStandard/Article/detail/653855?ref=25 AIDS treatment provider says the high price of Merck's Isentress is limiting patient access. Merck says banning its reps is what limits access. While Mom and Dad are fighting, does the patient lose out? 2010-01-27T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/653855null HTML http://pharmexec.findpharma.com/pharmexec/Kalido-Accela-Form---White-paper-Data-Governance-B/ArticleStandard/Article/detail/653853?ref=25 Kalido Accela Form - White paper: Data Governance: Business Data You Can Believe In 2010-01-27T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/653853null HTML http://pharmexec.findpharma.com/pharmexec/Business-Intelligence-Case-study-Abbott-Laboratori/ArticleStandard/Article/detail/653842?ref=25 Business Intelligence Case study: Abbott Laboratories - Kalido Whitepaper 2010-01-27T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/653842null PDF http://pharmexec.findpharma.com/pharmexec/Strategy/Reinventing-the-Market-Research-Function/ArticleStandard/Article/detail/651665?ref=25 In a disruptive era of change, old-fashioned intuition still counts. 2010-01-27T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651665/functions_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651665null XML http://pharmexec.findpharma.com/pharmexec/Kalido-KONA-Information-Appliance-for-Pharmaceutic/ArticleStandard/Article/detail/653843?ref=25 Kalido KONA Information Appliance for Pharmaceutical Sales & Marketing Analytics - Kalido whitepaper 2010-01-27T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/653843null PDF http://pharmexec.findpharma.com/pharmexec/Kalido-Accela-Form---Business-Intelligence-Case-st/ArticleStandard/Article/detail/653854?ref=25 Kalido Accela Form - Business Intelligence Case study: Abbott Laboratories 2010-01-27T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/653854null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/UCB-sponsored-PatientsLikeMe-Site-is-Live/ArticleStandard/Article/detail/653856?ref=25 All eyes are on PatientsLikeMe's new epilepsy site. The social network is backed by UCB, but the pharma firm is taking a hands-off approach. Is this the future of pharma social media? 2010-01-27T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/653856null HTML http://pharmexec.findpharma.com/pharmexec/Kalido-Accela-Form---Solution-brief-Kalido-KONA-In/ArticleStandard/Article/detail/653852?ref=25 Kalido Accela Form - Solution brief: Kalido KONA Information Appliance for Pharmaceutical Sales & Marketing Analytics 2010-01-27T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/653852null HTML http://pharmexec.findpharma.com/pharmexec/Data-Governance-Business-Data-You-Can-Believe-In--/ArticleStandard/Article/detail/653844?ref=25 Data Governance: Business Data You Can Believe In - Kalido Whitepaper 2010-01-27T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/052010/653844null PDF http://pharmexec.findpharma.com/pharmexec/Noteworthy/Pharma-Unplugged-Episode-4-Give-Until-It-Hurts/ArticleStandard/Article/detail/653224?ref=25 GAO reviews price hikes in branded drugs, FDA opens up to public, and pharma opens its wallet for Haiti. All on this week's Pharma Unplugged. 2010-01-22T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/042010/653224/pharmaunplugged_120x90_thumbnail_thumbnail_thumbnail_thumbnail.gif http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/042010/653224null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Witty-Opens-GSK-Library-for-Free-Access-to-Malaria/ArticleStandard/Article/detail/652833?ref=25 GlaxoSmithKline announced that it would open up its library of prospective molecules and investigational vaccines. This move gives researchers free access to study experimental treatments for illnesses that plague the world's poorest countries. 2010-01-20T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/042010/652833null HTML http://pharmexec.findpharma.com/pharmexec/Sales/The-Big-Reset/ArticleStandard/Article/detail/651666?ref=25 Pharm Exec's 2010 crystal ball reveals an industry in upheaval on many fronts. Is going back to the future the answer? 2010-01-20T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651666/Rest_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651666null XML http://pharmexec.findpharma.com/pharmexec/Whitepaper/Pharma-Complaint-Management--Emerging-Challenges-a/ArticleStandard/Article/detail/652283?ref=25 Product Complaints Management is an essential and critical component in the Pharmaceutical industry from the regulatory and compliance perspective. Immediate and real-time response to urgent customer requests and returns is critical in the industry, because product failure can truly be a fatal situation for customers ? something that can translate to a legal exposure for manufacturers. Hence, there is a need of a single, uniform, and secured platform to manage product complaints right from initiation through closure. 2010-01-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/042010/652283null REMOTE http://pharmexec.findpharma.com/pharmexec/Pharma-Complaint-Management--Emerging-Challenges-a/ArticleStandard/Article/detail/652009?ref=25 Pharma Complaint Management : Emerging Challenges and Solutions - Infosys Tech 2010-01-14T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/652009null PDF http://pharmexec.findpharma.com/pharmexec/Infosys-Accela-Form---Pharma-Complaint-Management-/ArticleStandard/Article/detail/652012?ref=25 Infosys Accela Form - Pharma Complaint Management : Emerging Challenges and Solutions 2010-01-14T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/652012null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Strategy-for-Security/ArticleStandard/Article/detail/648658?ref=25 A new pharma consortium focuses on securing the supply chain upstream. Pharm Exec interviews Rx360 to learn more. 2010-01-13T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648658/security_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648658null XML http://pharmexec.findpharma.com/pharmexec/Europe+News/EC-to-Scrutinize-Patent-Settlements/ArticleStandard/Article/detail/651790?ref=25 January 13, 2010. 2010-01-13T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651790null HTML http://pharmexec.findpharma.com/pharmexec/Europe/Recruiting-and-Retaining-RampD-Staff-in-a-Recessio/ArticleStandard/Article/detail/651610?ref=25 Dr Kay Wardle of RSA examines the impact of short-term survival strategies on pre-clinical R&D organizations. 2010-01-13T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651610null HTML http://pharmexec.findpharma.com/pharmexec/Regulatory/FDA-Basics-Brings-the-Agency-Out-of-the-Closet/ArticleStandard/Article/detail/651794?ref=25 The push for government transparency continues with Phase I of FDA's plan to expose the inner workings of that secretive cabal known as the Food and Drug Association. First up, fancy new FAQs. 2010-01-13T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651794null HTML http://pharmexec.findpharma.com/pharmexec/Regulatory/GAO-Seeks-Price-Spike-Explanation/ArticleStandard/Article/detail/651795?ref=25 At time when people can't even get a 3 percent cost-of-living increase, how can pharma justify price hikes pushing 500 percent (in some categories). A new study by the government's General Accountability Office examines why drug products took a massive price leap in recent years. 2010-01-13T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651795null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/GSKs-Andrew-Witty-New-EFPIA-President/ArticleStandard/Article/detail/650400?ref=25 January 06, 2010. 2010-01-06T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022010/650400null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Novartis-Bids-Big-on-Alcon/ArticleStandard/Article/detail/650517?ref=25 It's just a few days into the new year and already a potential megamerger has been announced: Novartis offered $39 billion for complete control of ocular drug manufacturer Alcon. 2010-01-06T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022010/650517null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Antidepressants-Might-Not-Be-A-Sure-Shot/ArticleStandard/Article/detail/650516?ref=25 A new JAMA study reveals that antidepressants might not have as strong an effect on people with less severe cases of depression. How this will affect the pharma industry, which once made heaps of cash with drugs like Prozac, remains to be seen. 2010-01-06T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022010/650516null HTML http://pharmexec.findpharma.com/pharmexec/Regulatory/Change-Agent/ArticleStandard/Article/detail/648653?ref=25 FDA Commissioner Margaret Hamburg has a history of health advocacy and a clear mandate to transform the agency. But can she succeed where others have failed? 2010-01-06T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648653/i1_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648653null XML http://pharmexec.findpharma.com/pharmexec/Europe+News/Novartis-Eyes-Full-Takeover-of-Alcon/ArticleStandard/Article/detail/650048?ref=25 January 04. 2010. 2010-01-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/022010/650048null HTML http://pharmexec.findpharma.com/pharmexec/Competition/War-Games-20/ArticleStandard/Article/detail/651671?ref=25 Competitive simulations can help pharma adjust to market changes by identifying effective action steps. 2010-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651671null XML http://pharmexec.findpharma.com/pharmexec/Thank-you-for-completing-our-Digital-Media-Survey/ArticleStandard/Article/detail/656681?ref=25 Thank you 2010-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/072010/656681null HTML http://pharmexec.findpharma.com/pharmexec/From+the+Editor/Definitions-for-the-New-Decade/ArticleStandard/Article/detail/651672?ref=25 Pharma must get its definitions right to be successful in the new decade. 2010-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651672null XML http://pharmexec.findpharma.com/pharmexec/Washington+Report/The-Big-Shift/ArticleStandard/Article/detail/651669?ref=25 Pharma must confront regulatory and marketing challenges in a global competitive environment. 2010-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651669null XML http://pharmexec.findpharma.com/pharmexec/Strategy/First-Do-No-Harm/ArticleStandard/Article/detail/651670?ref=25 Designing and deploying company copay offset programs without devaluing the brand. 2010-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651670/HarmThump_thumbnail.jpg XML http://pharmexec.findpharma.com/pharmexec/Marketing/Build-a-Better-Lunch-Table/ArticleStandard/Article/detail/651667?ref=25 In a new era of research partnerships, targeted information databases can improve collaborative decision making and speed new medicines to market. 2010-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651667null XML http://pharmexec.findpharma.com/pharmexec/Marketing/Patient-Partnerships-Under-Scrutiny/ArticleStandard/Article/detail/651668?ref=25 New tools are beig applied to make patient advocacy powerful and measurable. 2010-01-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/032010/651668null XML http://pharmexec.findpharma.com/pharmexec/Europe+News/Acquisition-boosts-Sanofis-consumer-healthcare-pro/ArticleStandard/Article/detail/649490?ref=25 December 23, 2009. 2009-12-23T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/522009/649490null HTML http://pharmexec.findpharma.com/pharmexec/Waters-Video-Showcase/ArticleStandard/Article/detail/648392?ref=25 Waters Video Showcase is accessible at waters.com/customers and is the largest such assemblage of expert testimonials in the industry. 2009-12-22T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648392null HTML http://pharmexec.findpharma.com/pharmexec/Podcasts/Pharma-Unplugged-Episode-3-Top-Five-News-Stories-i/ArticleStandard/Article/detail/649277?ref=25 George Koroneos and Reid Paul cover the top five trends and news stories in the pharmaceutical industry for 2009. 2009-12-21T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/522009/649277/pharmaunplugged_120x90_thumbnail_thumbnail_thumbnail.gif http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/522009/649277null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/Corrupt-Practices-Cost-Healthcare-23-Billion/ArticleStandard/Article/detail/649111?ref=25 December 18, 2009. 2009-12-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/649111null HTML http://pharmexec.findpharma.com/pharmexec/Europe/Survival-of-the-Dumbest/ArticleStandard/Article/detail/649064?ref=25 Definitions of the same management strategy terms can vary significantly between industry and academia, observes Dr Brian D. Smith. 2009-12-18T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/649064null HTML http://pharmexec.findpharma.com/pharmexec/Europe/Pharmas-New-Commercialization-Model/ArticleStandard/Article/detail/648932?ref=25 Quintiles' Jim Featherstone asks what the end of the blockbuster generation means for the sales operation?s business model and how pharma should react to the transition. 2009-12-17T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648932null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/MampAs-Set-to-Dominate-Pharma-Until-2014/ArticleStandard/Article/detail/648955?ref=25 December 17, 2009. 2009-12-17T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648955null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/GSK-Makes-Physician-Payments-Public/ArticleStandard/Article/detail/648745?ref=25 Transparency can be a double-edged sword - especially if you are a doctor receiving money to speak on behalf of a drug company. Sure the pay day is nice, but does the public outing open you up to scrutiny? 2009-12-16T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648745null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Gilead-and-Elan-Struggle-with-Clinical-Trials/ArticleStandard/Article/detail/648744?ref=25 It's been a tough week for clinical trials: One drug got canned and another was re-tuned in the wake of failed end points and patient deaths. 2009-12-16T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648744null HTML http://pharmexec.findpharma.com/pharmexec/Regulatory/Sanofi-Gets-a-Bad-Batch-of-H1N1-Vaccines/ArticleStandard/Article/detail/648743?ref=25 Sanofi-Aventis is recalling hundreds of thousands of doses of the childrens' version of its H1N1 vaccine. Conspiracy theorists are going to have a field day. 2009-12-16T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648743null HTML http://pharmexec.findpharma.com/pharmexec/Europe+News/Personalized-Medicine-Market-To-Grow-11-Annually/ArticleStandard/Article/detail/648493?ref=25 December 15, 2009. 2009-12-15T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648493null HTML http://pharmexec.findpharma.com/pharmexec/Argentina--market-Reports/ArticleStandard/Article/detail/647994?ref=25 2009-12-11T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502009/647994null PDF http://pharmexec.findpharma.com/pharmexec/Europe+News/Scottish-Life-Science-Sector-Receives-Euro-26-Mill/ArticleStandard/Article/detail/647663?ref=25 11 December. 2009-12-10T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502009/647663null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Feds-Team-with-Drugmakers-to-Curb-Opioid-Misuse/ArticleStandard/Article/detail/647504?ref=25 Painkiller abuse has become so prevalent that FDA is working with pharma to create a strategy for handling misuse of all drugs across the entire opioid category. 2009-12-09T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502009/647504null HTML http://pharmexec.findpharma.com/pharmexec/Marketing/Rx-Club-Awards-2009-Spotlight-on-Synergy/ArticleStandard/Article/detail/647465?ref=25 This year's winning brand advertising campaigns convey compelling messages with eye-catching graphics and creative copy. 2009-12-09T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502009/647465/RxClub_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502009/647465null PDF http://pharmexec.findpharma.com/pharmexec/Web+Exclusives/The-New-Four-Ps-of-Marketing/ArticleStandard/Article/detail/647481?ref=25 The rules of the game have changed. While pharmaceutical executives have been busy trying to keep up with a radically shifting marketing landscape, technology has swept in and changed everything marketers held sacred. 2009-12-09T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502009/647481null HTML http://pharmexec.findpharma.com/pharmexec/News+Analysis/Pharma-Comes-Under-Fire-for-Jump-in-Rx-Prices/ArticleStandard/Article/detail/647503?ref=25 Drug manufacturers came under fire at a hearing of the House Energy and Commerce?s health subcommittee for bumping drug prices 10 percent this year. Pharma claims rumors that it?s boosting costs in anticipation of healthcare reform are baseless, but the industry could be facing an uphill battle. 2009-12-09T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502009/647503null HTML http://pharmexec.findpharma.com/pharmexec/R%26D/2010-Forecast-Key-Products-and-Leading-Therapeutic/ArticleStandard/Article/detail/647353?ref=25 Alexandra Kibble of Thomson Reuters identifies the products and therapy areas to watch next year. 2009-12-08T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502009/647353/Thomson-Reuters_thumbnail.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502009/647353null HTML http://pharmexec.findpharma.com/pharmexec/Pharma-Unplugged-Episode-2--Layoffs-amp-Bonuses/ArticleStandard/Article/detail/647063?ref=25 Reid Paul, Editor-in-Chief of Pharmaceutical Representative Magazine joins host George Koroneos to discuss the top five pharmaceutical industry news stories of the week 2009-12-07T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502009/647063/pharmaunplugged_120x90_thumbnail_thumbnail.gif http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/502009/647063null HTML http://pharmexec.findpharma.com/pharmexec/Europe+Features/2010-Products-and-Therapy-Areas-to-Watch/ArticleStandard/Article/detail/645698?ref=25 Thomson Reuters' global pharma forecast for next year. 2009-12-04T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/492009/645698/thomson2_main.jpg http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/492009/645698null HTML http://pharmexec.findpharma.com/pharmexec/Sales/Layoffs-and-Job-Cuts-Brewing-at-Sanofi-Aventis/ArticleStandard/Article/detail/645278?ref=25 With the fourth quarter quickly coming to a close, talks of job cuts are once again in the air. The first major layoffs could be coming at Sanofi-Aventis, which is rumored to be slashing up to 1,500 positions. 2009-12-02T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/492009/645278null HTML http://pharmexec.findpharma.com/pharmexec/Strategy/Report-Sees-Huge-Pharma-Tax-Hike-Over-Next-Decade/ArticleStandard/Article/detail/645277?ref=25 A new study of industry tax professionals conducted by PricewaterhouseCoopers predicts higher taxes for Big Pharma in the wake of the global economic downturn. What can your company do to remain competitive and discover new incentives? 2009-12-02T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/492009/645277null HTML http://pharmexec.findpharma.com/pharmexec/R%26D/Fight-or-Flight/ArticleStandard/Article/detail/648660?ref=25 As the old orthodoxy shatters, pharma must stand firm or leave the field. 2009-12-01T05:00:00Z http://pharmexec.findpharma.com/pharmexec/data/articlestandard/pharmexec/512009/648660null XML